= flow cytometry; NTD = no type determined; SPRCA = solidphase RBC adherence assays; TAT = turn-around time. 
B
efore RBC transfusion, blood samples from donors and recipients are tested to determine their ABO group and D type, to detect unexpected RBC alloantibodies, and to confirm cross-match compatibility. These immunohematology assays represent a subset of pretransfusion testing, which also includes infectious disease serology, counting of residual WBCs in filtered blood components, platelet cross-matching, and additional assays.
Routine immunohematology testing has historically been performed by centrifuging RBCs and antibodies in test tubes followed by a visual determination of the extent of RBC agglutination. Although standard tube testing is still considered by many to be the de facto "gold standard" for immunohematology, this assay is labor intensive, not amenable to automation, and the results are operator dependent. With a decline in laboratory technical staff trained to perform standard tube testing, this assay is becoming increasingly impractical.
Column agglutination technology (CAT) (ID-Micro Typing System, Ortho-Clinical Diagnostics, Raritan, NJ) 1 and solid-phase RBC adherence assays (SPRCA) (Capture-R, Immucor, Norcross, GA) 2 overcome some deficiencies of standard tube testing. They eliminate tedious washing steps (CAT), have semiobjective readouts, and have been commercialized as automated or semiautomated workstations. However, their reagent and disposable costs are significantly greater than for standard tube testing, throughput can be slow and not suited for emergency testing, and their performance in detecting weak antibody-antigen interactions has been questioned. 3 Moreover, these methodologies are not adaptable to many other pretransfusion tests.
We sought an alternative technology for immunohematology testing that is accurate, rapid, cost effective, and compatible with other assays. We describe here the basis for a multifunctional immunohematology workstation that uses flow cytometry (FC) for assay readout. FC has previously been used for specialized immunohematology applications including quantitation of RBC antigen density, 4 ,5 detection of antigen variants, 6 and quantitation of antibody binding to RBCs. 7 This technology has also been used for quantitation of residual WBCs after filter WBC reduction, 8, 9 detection of feto-maternal hemorrhage, 10 platelet cross-matching, [11] [12] [13] and other applications. [14] [15] [16] Despite this wide range of applications, use of FC for standard immunohematology testing has been hampered by the propensity of large RBC agglutinates to form during antibody staining. 4, 16, 17 Because FC requires sampling of individual cells through small-bore apertures, RBC agglutinates can have adverse effects, including blocking of the flow cell. In the present report, we describe an approach that minimizes agglutination during the staining procedure and thus allows accurate detection of RBC-antibody interactions by FC. This technique should make automated FC pretransfusion testing feasible on a cost-effective and high-throughput basis.
MATERIALS AND METHODS

Samples, reagents, and supplies
Samples were obtained from discarded blood specimens submitted to the Emory University Hospital Blood Bank. This protocol was approved by the Emory University Human Investigations Committee. Standard blood typing reagent antibodies and RBCs were obtained from OrthoClinical Diagnostics (Raritan, NJ) or Immucor (Norcross, GA). PE-labeled secondary antibodies were obtained from Jackson ImmunoResearch Laboratories (West Grove, PA). Directly fluoresceinated anti-D was prepared by labeling anti-D containing human gammaglobulin fraction (WinRho SDF, Cangene, Winnipeg, Canada) with FITC using a commercially available kit (Pierce Biotechnology, Rockford, IL). Antibody and RBC working dilutions were determined through empirical studies and were made in 0.9-percent normal saline. A variety of 96-well microtiter filter plates were tested, although most studies utilized plates with 0.2 µm polyvinylidene difluoride filters (Corning, Acton, MA). The bottom of each well is perforated and covered by a filter such that the application of vacuum beneath the plate draws fluid through the filter, while material larger than the nominal pore size of the filter is retained in the microtiter well.
Flow cytometry staining
The fluorescent staining protocol for FC is summarized in Table 1 . In initial studies, RBC-antibody manipulations were performed in round-bottom 12 ¥ 75-mm polystyrene or 10 ¥ 75-mm glass tubes. For all assays, except as noted below, a minimum of 20,000 events were acquired on a flow cytometer (Becton-Dickinson FACScan, San Jose, CA).
ABO RBC grouping
Patient RBCs were added to two tubes, followed by the addition of mouse anti-A to one tube and anti-B to the other (BioClone Anti-A and Anti-B murine monoclonal IgM blends; 1-in-100 to 1-in-1000 dilutions from stock; Ortho-Clinical Diagnostics). For some studies, purified mouse IgM was used as an isotype control (Sigma-Aldrich; St. Louis, MO). After incubation, tubes were centrifuged at 1000 ¥ g for 20 seconds to pellet RBCs. The supernatants were discarded, saline was added, and the samples were centrifuged again for a total of four washes. PE-labeled antimouse IgM was added, the RBC pellets were dispersed by vigorous repetitive pipetting and vortexing, and the mixtures were incubated followed by two washes. Any remaining RBC aggregates were dispersed as above. Forward-and side-scatter gates were set to select intact RBCs for analysis (generally >90% of all events). Fluorescence in FL-2 channel was used to quantitate PE-labeling of RBCs. Replicate negative controls were performed, and the results were used to determine the threshold for positive reactions.
D typing
Patient RBCs were added to two tubes followed by either FITC-conjugated human anti-D (1 in 100) or saline (control). PEG (molecular weight 3350; Sigma-Aldrich) was added as a potentiator. The mixtures were incubated, washed four times, and analyzed using the FL-1 channel to quantitate FITC-labeled RBCs.
ABO serum testing
Group A, B, or O reagent RBCs were added to three separate tubes followed by patient plasma (or serum). The mixtures were washed four times, the pellets were resuspended in PE-labeled antihuman IgM, and after a 5-minute incubation the samples were washed and acquired in the FL-2 channel.
RBC alloantibody testing
RBCs from a three-cell screening panel were added to three tubes, followed by patient plasma and/or serum and PEG. The mixtures were incubated and washed, and a PEconjugated antihuman IgG antiserum was added before FC.
Filter plate technique
Assays were performed similarly when 96-well microtiter filter plates were used, except RBCs were washed by manually applying vacuum to individual wells using a Bio-Dot apparatus (Bio-Rad Laboratories, Hercules, CA). Typically, only a fraction of the pressure (-1 to -5 inches Hg) generated by standard vacuum systems was needed to rapidly aspirate fluid through the filter. At the conclusion of each vacuum step, RBCs were readily dislodged from the filter surface for subsequent manipulation. Loss or fragmentation of RBCs occurred infrequently and did not affect results. After staining, RBCs were transferred to 12 ¥ 75-mm tubes for manual data acquisition and analysis by FC. Occasionally (<5% of samples) there were insufficient RBCs to acquire 20,000 events, and 10,000 were acquired instead. Because RBC agglutination was minimal in this assay configuration, pipetting and vortexing were not necessary before FC. For the present studies, all sample transfer steps, as well as tube and plate labeling, were performed manually. Sample identities were confirmed by an independent observer to eliminate transcription and identification errors. This methodology is the subject of a patent application (Serial No. 09/773 826).
CAT and standard tube testing
Gel-column cards were used to perform forward and reverse ABO grouping and alloantibody screens (OrthoClinical Diagnostics). Standard tube testing was performed according to usual procedures, including alloantibody detection by the LISS-IAT. 18 All samples were tested and interpreted without knowledge of results from other assays.
RESULTS
FC methods for ABO grouping and D typing
For the initial FC studies, antibody staining and washing were performed in round-bottom test tubes. Samples with unambiguous ABO grouping and D typing results (by CAT) were first used to optimize FC assay parameters, including RBC concentration, antibody titer, use of potentiators, incubation time and temperature, and washing conditions. Despite these efforts, RBC agglutinates frequently formed in the tubes, although they could usually be dispersed. In some cases residual agglutinates occluded the cytometer flow cell, and these samples could not be analyzed. Nonetheless, the resulting staining protocol (Table  1) produced encouraging results (Fig. 1) Tube-based FC methods were then used for ABO grouping and D typing of 222 randomly selected samples, which were also tested by CAT and standard tube methods. Of the 222 samples, 202 (91.0%) typed identically by each test. The remaining 20 samples gave discordant results that were subsequently resolved by further analysis including testing for unexpected antibodies, prolonged incubation for reverse types, A1 typing, and testing for weak D (Table 3 ). For nine of these samples, no type was determined (NTD) by CAT due to disagreement between the forward and reverse types. CAT also failed to identify two mixed-field reactions and a weak D, while incorrectly identifying six A1-negative blood samples as having mixed-field reactions. Overall, 2 of the 20 discrepant samples were typed correctly by CAT, for an accuracy of 204 out of 222 (91.9%). For standard tube testing, 9 of the 20 samples yielded the correct results for an overall accuracy of 211 out of 222 (95.0%). In contrast, 18 of the 20 samples were typed correctly by FC, while the two remaining samples were NTD due to weak alloantibodies. The accuracy of FC testing was 99.1 percent (220/222 samples). Thus, FC performed as well CAT and standard tube testing for ABO grouping and D typing of typical blood samples and better than other methodologies when samples had abnormalities such as rouleaux, autoantibodies, weak alloantibodies, and mixed-field reactions.
FC methods for RBC alloantibody testing
Using test tubes for sample preparation, specimens containing strong alloantibodies (3+ and 4+ by CAT) were used to develop a protocol for RBC alloantibody detection by FC (Table 1) 
Development of FC methodologies compatible with automation
These studies confirmed that FC could detect antibody-RBC interactions with accuracy and sensitivity comparable to commercially available methodologies. However, they also confirmed that RBC agglutinates formed in test tubes during staining can occlude the cytometer ) were also included. The average MFI for negative alloantibody controls was 4.04 (SD = 0.44). Of 51 samples negative for alloantibodies by CAT, 49 were also negative by LISS-IAT and FC. The remaining two samples, negative by CAT, in fact con-and prevent analysis, as was previously described. 4, 16, 17 Because of this drawback, alternate approaches of preparing RBCs for FC were investigated.
Automated laboratory systems frequently employ disposable microtiter filter plates and vacuum stations for sample washing. We examined a variety of filter plates as substitutes for test tubes and determined that plates containing 0.2-µm PVDF filters optimally preserved RBC integrity during vacuum washing. These plates were then used for ABO grouping and D typing as described above (Table 1) An additional 26 samples were tested that had abnormalities including weak reverse typing reactions (<2+ by CAT), mixed-field reactions, or rouleaux. A total of 22 typed correctly by FC, while 4 were NTD due to weak reverse reactions that were not detected; of these, two samples were also NTD by CAT. Overall, 104 of 109 samples (95.4%) typed correctly by FC when stained in filter plates, while the remaining samples were flagged as NTD for further analysis. None of the samples was incorrectly typed by FC. CAT showed 98.2 percent accuracy and a 1.8 percent NTD rate.
The filter-plate method was also used to screen for unexpected alloantibodies in 175 samples containing 238 alloantibodies and 50 samples without alloantibodies. Representative results for FC are shown in Fig. 4 . The average MFI for negative controls was 3.43 (SD = 0.65). Of the 175 samples that were positive by CAT, 169 (96.6%) were also positive by FC, while 160 (91.4%) were positive by LISS-IAT. Among the six samples that were negative by FC, one was a weakly reactive anti-E, two were 1+ antiKell, and three were anti-M. These three anti-M were subsequently detected when the staining procedure was modified to include both antihuman IgG and IgM secondary antibodies. Of 50 samples that tested negative by CAT, 49 were also negative by LISS-IAT and FC. However, one sample had detectable alloantibodies by LISS-IAT and FC. When the one positive sample that tested negative by CAT is included (n = 176 total positive samples), the accuracy rates of FC, CAT, and LISS-IAT were 98.3, 99.4, and 91.5 percent, respectively. Thus, in this study set, FC performed comparably to CAT and better than LISS-IAT.
Although the FC results were similar whether washing was performed in tubes or in microtiter filter plates, the extent of RBC agglutination was significantly different. While samples washed in tubes were vigorously pipetted and vortexed, RBC agglutinates remained in up to 10 percent of samples and produced irregular histograms (Fig. 5A-C) . Approximately 1 percent of samples had large enough agglutinates to occlude the cytometer. In contrast, there were no visible RBC agglutinates in filter plates even though no efforts were made to disperse the RBCs (Fig.  5D-F) . The difference in agglutination is likely due to the fact that centrifugation in tubes collects RBCs into a tight pellet, facilitating the formation of agglutinates. The vacuum technique separates and distributes RBCs over the entire surface area of the filter during washing steps, preventing significant agglutination. There were no consistent differences in the resulting fluorescence intensity with the two methods.
DISCUSSION
Although manual tube-based immunohematology testing remains the standard in many laboratories, this technique is labor intensive, is not suited to automation, and requires highly skilled technologists for accurate results. Alternative methodologies have been commercialized to address these deficiencies, including CAT, SPRCA, and amphitheater plate-mediated hemagglutination (Olympus PK7200, Olympus of America, Melville, NY). Other novel methods, such as a microplate-based agglutination assay 19 and UV-visible spectrophotometric typing, 20, 21 are also in development.
The most important requirement for any immunohematology assay must be accuracy. Standard tube testing, CAT, SPRCA, and amphitheater hemagglutination have shown sufficient accuracy to obtain FDA approval for commercialization. Herein, we demonstrate that the accuracy of FC testing compares very favorably with that of standard tube testing and CAT. When samples were stained in tubes before FC, ABO group and D type were correctly determined for 99.1 percent of clinical samples. By comparison, accuracy rates of CAT and standard tube testing were 91.9 and 95.0 percent for the same sample set, respectively. FC also detected 99.5 percent of clinically relevant alloantibodies, while CAT and LISS-IAT identified 98.9 percent and 94.7 percent, respectively. To overcome the necessity of dispersing RBC agglutinates before FC, we optimized a vacuum filtration method that eliminated the need for vigorous vortexing and pipetting or caustic agents like glutaraldehyde. 4, 16, 17, 22 Using the filter plate FC technique, 104 of 109 samples (95.4%) were correctly typed for ABO and D, whereas the remaining five samples were read as NTD. Although the 4.6-percent NTD rate was higher than when samples were stained in tubes, it is still less than the 6-percent rate mandated by recent FDA guidance. 23 More recently, technical modifications have reduced the NTD rate to less than 1 percent (unpublished data). Further improvements might result through the use of anti-IgG in combination with anti-IgM for ABO serum testing. Using the filter plate FC method, 98.3 percent of alloantibody-containing samples were correctly identified, compared to 99.4 percent with CAT and 91.5 percent with LISS-IAT. Importantly, these comparisons were made using authentic clinical samples with abnormalities including weak alloantibodies, rouleaux, autoantibodies, and mixed-field reactions, which are not uncommon in hospitalized patients. In contrast, other recently described methods have only used samples from healthy donors, and none of these methods has been applied to routine alloantibody identification. [19] [20] [21] [22] We have not yet examined assay performance for pretransfusion cross-matches, but we anticipate that accuracy will be similar to that seen for ABO serum testing ("immediate spin" cross-match) and RBC alloantibody testing ("Coombs" cross-match).
After accuracy, other considerations include cost, turn-around time (TAT), and compatibility with additional pretransfusion tests. Despite the high labor costs of standard tube testing, many facilities continue to rely on this methodology because of the offsetting inexpensive equipment and reagents. However, the cost benefits of standard tube testing may not be realizable due to a shortage of qualified technologists. For this reason, many facilities have found it necessary to implement automation, even though automated devices have higher associated capital and disposables costs. Currently available immunohematology workstations range in capital cost from $60,000 to $350,000. 3 We estimate that an automated FC testing platform would be in the middle of this range. However, unlike methods such as CAT and SPRCA, the FC technology utilizes relatively inexpensive disposables and reagents and thus over time may be less expensive to implement.
Assay TAT is important in the hospital transfusionservice setting, particularly if emergency testing is performed. The TAT to determine a blood type and test for RBC alloantibodies is approximately 30 minutes for CAT and 45 minutes for SPRCA. Based on current protocols (Table 1) , we estimate that an FC workstation could perform these assays on a single sample in approximately 20 minutes. When multiple samples are batched, we estimate 20 samples can be tested in 45 minutes. These times may be reduced through further assay optimization.
Although the assays in the present report were performed manually, we are currently investigating several commercially available liquid-handling platforms that can automate all of the steps in this procedure for highthroughput testing. Unlike other technologies, this automated system could serve as a platform for a variety of pretransfusion tests. For example, FC has been used to quantitate residual WBCs after filtration, 8, 9 detect antibody binding to platelets, [11] [12] [13] detect bacteria, 24 identify feto-maternal hemorrhage, 10, 25, 26 and as an alternative to conventional serologic methods to detect pathologic antibodies in serum (such as antiviral antibodies). 27 FC can also be used for determination of RBC survival after transfusion, 28, 29 quantitation of RBC blood group antigen density, 4, 5 and determining expression of blood group antigen variants. 6 With appropriate reagents, all of these assays should be compatible with an automated FC workstation.
In conclusion, we have described an accurate FC methodology for ABO grouping, D typing, and testing for unexpected RBC alloantibodies. Although the studies described herein were performed with samples from hospitalized patients, this technology should also be applicable to testing donor samples. We are currently developing a fully automated prototype incorporating this technology and estimate that the resulting workstation will be competitive with current commercially available devices in terms of cost and TAT. In addition, through the use of FC, this workstation should be compatible with other pretransfusion tests, including residual WBC counting and detection of bacterial contamination. 
